Insmed (INSM) & Ocata Therapeutics (OCAT) Head to Head Contrast

Insmed (NASDAQ: INSM) and Ocata Therapeutics (NASDAQ:OCAT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.


This table compares Insmed and Ocata Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Insmed N/A -78.04% -57.74%
Ocata Therapeutics -4,564.66% -103.02% -46.18%

Institutional & Insider Ownership

99.1% of Insmed shares are owned by institutional investors. 5.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Insmed and Ocata Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insmed N/A N/A -$192.64 million ($2.86) -8.52
Ocata Therapeutics N/A N/A N/A ($0.70) N/A

Insmed is trading at a lower price-to-earnings ratio than Ocata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Insmed and Ocata Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed 0 2 6 0 2.75
Ocata Therapeutics 0 0 0 0 N/A

Insmed presently has a consensus price target of $37.25, indicating a potential upside of 52.79%.


Insmed beats Ocata Therapeutics on 6 of the 8 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

About Ocata Therapeutics

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with's FREE daily email newsletter.

Leave a Reply